



83 Clemenceau Avenue #12-03 UE Square
Singapore 239920

VIA EDGAR

April 30, 2018

U.S. Securities and Exchange Commission
Office of Healthcare and Insurance
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549

Attn: Ms. Irene Paik
Mr. Christopher Edwards

**Re: ASLAN Pharmaceuticals Limited
Registration Statement on Form F-1
File No. 333-223920**

Acceleration Request

Requested Date: Wednesday, May 2, 2018
Requested Time: 4:00 P.M. Eastern Time

Ladies and Gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the "**Registrant**") hereby requests that the Securities and Exchange Commission (the "**Commission**") take appropriate action to cause the above-referenced Registration Statement on Form F-1 to become effective on May 2, 2018, at 4:00 p.m. Eastern Time, or as soon thereafter as is practicable, or at such later time as its counsel may orally request via telephone call to the staff. The Registrant hereby authorizes each of Robert Phillips and Charles Kim of Cooley LLP, counsel to the Registrant, to make such request on its behalf.

Once the Registration Statement has been declared effective, please orally confirm that event with Robert Phillips of Cooley LLP at (415) 693-2020, or in his absence, Charles Kim at (858) 550-6049. Thank you for your assistance with this matter.

Sincerely,

ASLAN Pharmaceuticals Limited

By: /s/ Carl Firth

Carl Firth, Ph.D.

Chief Executive Officer and Chairman

cc: Kiran Asarpota, *ASLAN Pharmaceuticals Limited*

Robert W. Phillips, *Cooley LLP*

Sean M. Clayton, *Cooley LLP*

Charles S. Kim, *Cooley LLP*

Patrick Loofbourrow, *Cooley LLP*

Alan F. Denenberg, *Davis Polk & Wardwell LLP*